We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note
Read MoreHide Full Article
In the latest trading session, Recursion Pharmaceuticals (RXRX - Free Report) closed at $4.01, marking a -8.03% move from the previous day. This change lagged the S&P 500's daily loss of 0.06%. Meanwhile, the Dow experienced a rise of 0.38%, and the technology-dominated Nasdaq saw a decrease of 0.44%.
Coming into today, shares of the biotechnology company had gained 36.25% in the past month. In that same time, the Medical sector gained 0.04%, while the S&P 500 gained 2.36%.
Investors will be eagerly watching for the performance of Recursion Pharmaceuticals in its upcoming earnings disclosure. The company's upcoming EPS is projected at -$0.24, signifying a 33.33% increase compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $8.42 million, up 62.57% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$0.94 per share and revenue of $40.32 million, which would represent changes of +34.72% and -46.01%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Recursion Pharmaceuticals. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.17% lower. Recursion Pharmaceuticals currently has a Zacks Rank of #4 (Sell).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 166, which puts it in the bottom 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow RXRX in the coming trading sessions, be sure to utilize Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest trading session, Recursion Pharmaceuticals (RXRX - Free Report) closed at $4.01, marking a -8.03% move from the previous day. This change lagged the S&P 500's daily loss of 0.06%. Meanwhile, the Dow experienced a rise of 0.38%, and the technology-dominated Nasdaq saw a decrease of 0.44%.
Coming into today, shares of the biotechnology company had gained 36.25% in the past month. In that same time, the Medical sector gained 0.04%, while the S&P 500 gained 2.36%.
Investors will be eagerly watching for the performance of Recursion Pharmaceuticals in its upcoming earnings disclosure. The company's upcoming EPS is projected at -$0.24, signifying a 33.33% increase compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $8.42 million, up 62.57% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$0.94 per share and revenue of $40.32 million, which would represent changes of +34.72% and -46.01%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Recursion Pharmaceuticals. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.17% lower. Recursion Pharmaceuticals currently has a Zacks Rank of #4 (Sell).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 166, which puts it in the bottom 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow RXRX in the coming trading sessions, be sure to utilize Zacks.com.